Details of the Drug Combinations

General Information of This Drug (ID: DMPWHU6)

Drug Name

V81444 DMPWHU6

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 1/2	[1]
Advanced cancer	2A00-2F9Z	Phase 1	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
V81444 + Panobinostat	DC6KDK4	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
V81444 + Ruxolitinib	DCIFECF	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02253745) Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.